Should We Add Screening of Age-Related Macular Degeneration to Current Screening Programs for Diabetic Retinopathy?

Ophthalmology

Volumn 122, Issue 11, 2015, Pages 2155-2156

  Chew, Emily Y ^a   Schachat, Andrew P ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN ANTIBODY;

AGE RELATED MACULAR DEGENERATION; BLINDNESS; DIABETIC RETINOPATHY; EDITORIAL; ETHNIC GROUP; HUMAN; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; SCREENING; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MACULAR DEGENERATION; MALE; MASS SCREENING; VISUAL SYSTEM EXAMINATION;

COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MASS SCREENING;

EID: 84955312058     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.08.007     Document Type: Editorial

References (16)

1. Chan CK, Gangwani RA, McGhee SM, et al. Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening. Ophthalmology 2015;122:2278-85.
2. J.D. Whited, S.K. Datta, L.M. Aiello, and et al. A modeled economic analysis of a digital tele-ophthalmology system as used by three federal health care agencies for detecting proliferative diabetic retinopathy Telemed J E Health 11 2005 641 651
3. J.C. Javitt, and L.P. Aiello Cost-effectiveness of detecting and treating diabetic retinopathy Ann Intern Med 124 1996 164 169
4. F.L. Ferris 3rd How effective are treatments for diabetic retinopathy? JAMA 269 1993 1290 1291
5. The Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS report no. 8 Arch Ophthalmol 119 2001 1417 1436
6. Age-Related Eye Disease Study 2 Research Group Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial JAMA 309 2013 2005 2015
7. Age-Related Eye Disease Study 2 Research Group Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report no. 3 JAMA Ophthalmol 132 2014 142 149
8. Age-Related Eye Disease Study Research Group Potential public health impact of age-related eye disease results. AREDS report no. 11 Arch Ophthalmol 121 2003 1621 1624
9. J.D. Stein, P.A. Newman-Casey, T. Mrinalini, and et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration Ophthalmology 121 2014 936 945
10. O.P. Gupta, G.C. Brown, and M.M. Brown Age-related macular degeneration: the costs to society and the patient Curr Opin Ophthalmol 18 2007 201 205
11. C. Hopley, G. Salkeld, J.J. Wang, and et al. Cost utility of screening and treatment for early age-related macular degeneration with zinc and antioxidants Br J Ophthalmol 88 2004 450 454
12. D.B. Rein, J.B. Saaddine, J.S. Wittenborn, and et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration Ophthalmology 114 2007 1319 1326
13. Q.S. You, L. Xu, H. Yang, and et al. Five-year incidence of age-related macular degeneration: the Beijing Eye Study Ophthalmology 119 2012 2519 2525
14. M. Yasuda, Y. Kiyohara, Y. Hata, and et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population: the Hisayama Study Ophthalmology 116 2009 2135 2140
15. R. Klein, B.E. Klein, M.D. Knudtson, and et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis Ophthalmology 113 2006 373 380
16. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-16.